Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study
In this real-world study of patients with RAASi use after SZC initiation, about two-thirds of patients had an optimized RAASi dose and more than a quarter of patients had a maximized RAASi dose within 6 months of starting SZC. Findings were consistent across sub-studies of patients with CKD, HF and treatment with MRA. SZC may support the maintenance of optimal RAASi therapy; however, further comparative analyses are warranted. Graphical abstract available for this article.
Authors
- Abiy Agiro (ORCID: https://orcid.org/0000-0002-2369-8507)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Ellen Colman
- Manasvi Sundar (ORCID: https://orcid.org/0000-0001-5858-8685)
- Fan Mu (ORCID: https://orcid.org/0000-0003-0252-0387)
- Arun Malhotra (ORCID: https://orcid.org/0000-0001-6656-7841)
- Jingyi Chen (ORCID: https://orcid.org/0009-0007-0141-2241)
- Ali Greatsinger
- Angela Zhao (ORCID: https://orcid.org/0009-0000-5508-2603)
Institutions
- AstraZeneca (France) (FR)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1007/s12325-025-03254-z
- Citations
- 2
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- AstraZeneca